MannKind

Yahoo Finance • yesterday

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in child... Full story

Yahoo Finance • yesterday

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care by introducing a new inhaled mealtime ins... Full story

Yahoo Finance • 19 days ago

H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets

MannKind Corporation (NASDAQ:MNKD) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, H.C. Wainwright increased its price target on MannKind Corporation (NASDAQ:MNKD) from $8 to $10 and kept its Buy rating on the stock. The resear... Full story

Yahoo Finance • last month

How The MannKind (MNKD) Story Is Shifting With Tyvaso DPI And Soft Mist Uncertainty

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. MannKind’s fair value estimate has been trimmed from US$7.50 to ab... Full story

Yahoo Finance • last month

Why MannKind Corporation (MNKD) is One of the Best Stocks Under $5 With Huge Upside Potential

MannKind Corporation (NASDAQ:MNKD) is one of the best stocks under $5 with huge upside potential. Mizuho cut the price target on MannKind Corporation (NASDAQ:MNKD) to $8 from $10 on April 13 and reaffirmed an Outperform rating on the share... Full story

Yahoo Finance • 2 months ago

Truist Securities Touts MannKind Corporation (MNKD) Prospects on Tyvaso Franchise Development

MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare penny stocks to buy according to hedge funds. On March 30, Truist Securities reiterated that MannKind (NASDAQ:MNKD) is a Buy with a $7 price target in response to positive tr... Full story

Yahoo Finance • 2 months ago

10 high-profitability small-cap stocks with lowest YTD performance in 2026

[Man looking at currency trading app on his smart phone from his home office] Alistair Berg A notable shift is underway in the small-cap market in 2026: profitable Russell 2000 companies are decisively outperforming their non-profitable c... Full story

Yahoo Finance • 2 months ago

Clinical Nutrition for Diabetes Care Market Report 2026-2030 Featuring Profiles of Key Players - Pfizer, Bayer, Sanofi-Aventis, Abbott Labs, Roche and More

Company Logo The rise of diabetes, demand for specialized nutrition, digital monitoring tools, and home-based management are key trends driving market growth Clinical Nutrition for Diabetes Care MarketClinical Nutrition for Diabetes Care... Full story

Yahoo Finance • 3 months ago

MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets

MannKind Corporation (NASDAQ:MNKD) is among the best NASDAQ penny stocks to buy according to analysts. On 26 February, MannKind Corporation (NASDAQ:MNKD) shared its plans at the Oppenheimer healthcare conference. The company said it expect... Full story

Yahoo Finance • 3 months ago

MannKind Corporation (MNKD): A Bull Case Theory

We came across a bullish thesis on MannKind Corporation on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on MNKD. MannKind Corporation's share was trading at $3.5000 as of February 25th. MNKD’s trailing and forw... Full story

Yahoo Finance • 5 months ago

Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?

Key Points CEO Michael Castagna sold 65,804 shares on Dec. 17, 2025, for a total value of approximately ~$395,482 at a weighted average price around $6.01 per share. This transaction represented 2.56% of Mr. Castagna's direct holdings, re... Full story

Yahoo Finance • 6 months ago

Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset

MannKind (MNKD) has been quietly grinding higher, with shares up about 4% over the past week and roughly 5% in the past 3 months, even as the year-to-date return remains negative. See our latest analysis for MannKind. That recent 1 day s... Full story

Yahoo Finance • 6 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially provide a cost-effective and convenient option to address episodes of fluid... Full story

Yahoo Finance • 7 months ago

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

MannKind $100,000 in scholarship funds to be distributed to at least 10 students living withdiabetes pursuing higher education in life sciences Alfred E. Mann Charities and MannKind are partnering with The Diabetes Link to launch the effo... Full story

Yahoo Finance • 7 months ago

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 202... Full story

Yahoo Finance • 8 months ago

MannKind's Afrezza under supplemental FDA review

[Diagnosis testing of patients.] metamorworks/iStock via Getty Images * MannKind Corporation (MNKD) announced that the U.S. FDA has accepted the supplemental marketing application seeking approval for Afrezza (insulin human) inhalation... Full story

Yahoo Finance • 8 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026 WESTLAKE VILLAGE,... Full story

Yahoo Finance • 8 months ago

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is ex... Full story

Yahoo Finance • 8 months ago

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocri... Full story

Yahoo Finance • 9 months ago

MannKind's Plan of Increasing Revenue Base, Advancing Potential Pipeline Enhances its Value Creation, Oppenheimer Says

MannKind's (MNKD) game plan of enhancing its revenue base, while also advancing a potential pipeline PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story